BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260515T001418
CREATED:20260318T153844Z
LAST-MODIFIED:20260318T153844Z
UID:43179-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:4th Obesity & Weight Loss Drug Development Summit
DESCRIPTION:Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment\, preserving functional health\, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies. \nThe obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins\, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026\, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality\, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free\, scalable solutions that promise to transform chronic disease management forever. \nThe 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year\, we are diving deep into the game-changing potential of multi-targeted portfolios\, novel biological pathways and new modalities for a precision medicine approach\, alongside the “Oral-First” revolution. \nHear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly\, and Merck & Co.\, as well as innovative biotechs such as Veru Inc.\, Canary Cure\, and Metsera\, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain. \nDon’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline. \nView the full event guide: https://ter.li/p453jn
URL:https://www.pharmajournalist.com/event/4th-obesity-weight-loss-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260515T001418
CREATED:20260506T130245Z
LAST-MODIFIED:20260506T130245Z
UID:43444-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit West
DESCRIPTION:Across the West Coast\, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development\, supporting patients for longer durations\, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive\, exception-based activity is now a visible\, repeatable function – bringing heightened expectations around governance\, post-trial access\, sustainability\, and real-world insight generation\, all while ensuring patients are not delayed or disadvantaged. \nThe 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams\, this summit brings together senior leaders across Access\, Medical Affairs\, Clinical Operations\, Regulatory\, and Clinical Supply to share how EAPs are being designed\, governed\, and scaled in today’s environment. \nOver three focused days\, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations\, to enabling providers and patient advocates\, designing post-trial access strategies\, managing long-duration and rare disease programs\, and applying real-world insights without slowing access. \nThis is not a theoretical discussion. It is a peer-led\, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next. \nTo know more visit: https://ter.li/gk0u1gt1
URL:https://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit-west/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR